Positive data for PTC124, one of the first potential therapies to address the basic defect in CF were published today in The Lancet. The Phase 2 data show that treatment with PTC124 improves the function of the faulty
|
1 min read
Share this article
Topics
About the CF Foundation
|
CFTR Modulators
CF Foundation Adapts Registry Reporting to New Race-Neutral Standards
News |
5 min read
Nearly 350 Advocates Urge Congressional Action During 17th Annual March on the Hill
News |
3 min read
Cystic Fibrosis Foundation Invests an Additional $5 Million in BiomX
News |
2 min read
Stay up to date with The Foundation
Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.